Details for Patent: 7,737,168
✉ Email this page to a colleague
Which drugs does patent 7,737,168 protect, and when does it expire?
Patent 7,737,168 protects TPOXX and is included in two NDAs.
This patent has thirty-five patent family members in thirteen countries.
Summary for Patent: 7,737,168
| Title: | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| Abstract: | Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus. |
| Inventor(s): | Jordan; Robert (Corvallis, OR), Bailey; Thomas R. (Pheonixville, PA), Rippin; Susan R. (Wilmington, DE) |
| Assignee: | Siga Technologies, Inc. (Corvallis, OR) |
| Application Number: | 10/561,153 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 7,737,168
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG | ⤷ Subscribe | ||||
| Siga Technologies | TPOXX | tecovirimat | SOLUTION;INTRAVENOUS | 214518-001 | May 18, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TPOXX IS INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 3 KG | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,737,168
| PCT Information | |||
| PCT Filed | June 18, 2004 | PCT Application Number: | PCT/US2004/019552 |
| PCT Publication Date: | December 29, 2004 | PCT Publication Number: | WO2004/112718 |
International Family Members for US Patent 7,737,168
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1638938 | ⤷ Subscribe | 301177 | Netherlands | ⤷ Subscribe |
| European Patent Office | 1638938 | ⤷ Subscribe | 2022C/521 | Belgium | ⤷ Subscribe |
| European Patent Office | 1638938 | ⤷ Subscribe | 122022000032 | Germany | ⤷ Subscribe |
| European Patent Office | 1638938 | ⤷ Subscribe | 2290024-5 | Sweden | ⤷ Subscribe |
| European Patent Office | 1638938 | ⤷ Subscribe | C202230021 | Spain | ⤷ Subscribe |
| Australia | 2004249250 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
